Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara...
https://pubmed.ncbi.nlm.nih.gov/37676681/Actively Recruiting
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-10-07
57
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of combining a PD-1 inhibitor called sintilimab with radiotherapy and immunonutrition support in patients with locally advanced or early stage esophageal squamous cell carcinoma who cannot tolerate standard chemoradiotherapy. This phase II, single-arm multicenter trial focuses on patients who have positive PD-L1 expression and are unsuitable for platin-based chemoradiotherapy due to factors like older age or other health issues. Previous studies have shown promising results using immunotherapy with chemoradiotherapy, motivating this investigation. Participants will receive concurrent treatment with radiotherapy doses of 50-60 Gy delivered in 25-30 sessions along with 200 mg of sintilimab every three weeks. Alongside these treatments, they will take an enteral nutritional emulsion TPF-T daily, adjusted between 600 and 1600 ml based on their nutritional status. After radiotherapy, consolidation immunotherapy with sintilimab continues for up to one year. This combined approach aims to improve progression-free survival while monitoring safety. Throughout the study, participants will undergo evaluations including imaging to assess tumor response, laboratory tests to monitor organ function, and tracking of adverse events. The primary outcome is the progression-free survival rate at one year, with secondary outcomes including response rates, overall survival, and safety measures at multiple time points up to three years. Participants will be closely monitored for treatment tolerance and disease progression during and after therapy, with the total study duration extending through the follow-up period.
CONDITIONS
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
J
Jianyang Wang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are assessed to confirm eligibility based on medical history, tumor characteristics, PD-L1 status, and organ function.
1 screening visit
Duration - Approximately 6 to 9 weeks
Participants receive radiotherapy in 25-30 sessions combined with sintilimab infusions every three weeks and daily enteral nutritional emulsion adjusted to nutritional status.
Multiple visits for radiotherapy and immunotherapy infusions
Duration - Up to 12 months
After radiotherapy, participants continue receiving sintilimab every three weeks as consolidation therapy for up to one year.
Regular infusions every three weeks
Duration - Up to 3 years
Participants are monitored with imaging and clinical assessments to evaluate tumor response, survival, and any side effects for up to three years after starting treatment.
Scheduled visits at months 3, 6, 12, 18, 24, and beyond
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara...
https://pubmed.ncbi.nlm.nih.gov/37676681/Yupei Yuan, Shihong Luo, Xiaomin Wang...
https://pubmed.ncbi.nlm.nih.gov/40251674/Nitin Ohri, Shruti Jolly, Benjamin T Cooper...
https://pubmed.ncbi.nlm.nih.gov/37988638/Sehhoon Park, Dongryul Oh, Yoon-La Choi...
https://pubmed.ncbi.nlm.nih.gov/35319779/Chen Li, Lijun Tan, Xiao Liu...
https://pubmed.ncbi.nlm.nih.gov/33949784/Yujia Zhu, Jing Wen, Qiaoqiao Li...
https://pubmed.ncbi.nlm.nih.gov/36990609/Yun Chen, Jinjun Ye, Zhengfei Zhu...
https://pubmed.ncbi.nlm.nih.gov/30920880/Yongling Ji, Xianghui Du, Weiguo Zhu...
https://pubmed.ncbi.nlm.nih.gov/34351356/Jing You, Shuchai Zhu, Jiancheng Li...
https://pubmed.ncbi.nlm.nih.gov/36402359/Yanxiao Liu, Zhiyong Zheng, Minghao Li...
https://pubmed.ncbi.nlm.nih.gov/35419831/Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead Sponsor